# EDGAR Filing Document

**Accession Number:** 0001597313
**File Stem:** 0001628280-23-007785
**Filing Date:** 2023-3
**Character Count:** 8571
**Document Hash:** 4b299f6fd24ba7905e81b26acd4aa014
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-23-007785.hdr.sgml**: 20230314

**ACCESSION NUMBER**: 0001628280-23-007785

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230313

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230314

**DATE AS OF CHANGE**: 20230314

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ViewRay, Inc.
- **CENTRAL INDEX KEY:** 0001597313
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **IRS NUMBER:** 421777485
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37725
- **FILM NUMBER:** 23729468

**BUSINESS ADDRESS:**
- **STREET 1:** 2 THERMO FISHER WAY
- **CITY:** OAKWOOD VILLAGE
- **STATE:** OH
- **ZIP:** 44146
- **BUSINESS PHONE:** 440-703-3210

**MAIL ADDRESS:**
- **STREET 1:** 2 THERMO FISHER WAY
- **CITY:** OAKWOOD VILLAGE
- **STATE:** OH
- **ZIP:** 44146

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Mirax Corp
- **DATE OF NAME CHANGE:** 20140116

?xml version="1.0" ? vray-20230313

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

_________________________________________________

**FORM 8-K**

_________________________________________________

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 13, 2023**

_________________________________________________

**ViewRay, Inc.**

**(Exact name of Registrant as Specified in Its Charter)**

_________________________________________________

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37725** | **42-1777485** |
| **(State or Other Jurisdiction**<br>**of Incorporation)** | **(Commission File Number)** | **(IRS Employer**<br>**Identification No.)** |

---

**1099 18th Street, Suite 3000, Denver, Colorado 80202**

**(Address of Principal Executive Offices, Zip Code)**

**Registrant's Telephone Number, Including Area Code: (440) 703-3210**

**Not applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

_________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.01 | VRAY | The Nasdaq Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

------

**Item 7.01 Regulation FD Disclosure.**

As disclosed in ViewRay, Inc.'s (the "Company") Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission on February 28, 2023, the Company has held a significant majority of its cash, cash equivalents, and short-term investments with Silicon Valley Bank ("SVB"). Beginning Monday, March 13, 2023, the Company moved the majority of its cash, cash equivalents, and short-term investments held at SVB to other financial institutions. At present, the Company holds less than 5% of its cash, cash equivalents, and short-term investments with SVB and intends to hold a de minimis amount with SVB going forward, pending the resolution of SVB's closure and receivership under the Federal Deposit Insurance Corporation (the "FDIC").

In addition, since November 2022, the Company has maintained a five-year loan facility agreement with MidCap Financial ("MidCap") and SVB (the "Agreement"), comprised of a term loan of up to $100 million and a revolving line of credit of up to $25 million. At present, the Company has $80 million in outstanding debt to MidCap and SVB under the Agreement. The Company is currently, and at all times has been, in compliance with the Agreement, including all financial covenants.

The Company notes that no material impact to operations has occurred or is expected to occur in connection with SVB's closure and receivership under the FDIC.

The information in this Current Report on Form 8-K is being furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information herein.

**Forward-Looking Statements**

This Current Report on Form 8-k contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this Current Report on Form 8-k that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, ViewRay's financial guidance for the full year 2023, anticipated future orders, anticipated future operating and financial performance, treatment results, therapy adoption, innovation, and the performance of the MRIdian systems. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize the MRIdian Linac System, demand for ViewRay's products, the ability to convert backlog into revenue and cash collections, the timing of delivery of ViewRay's products, the timing, length, and severity of the COVID-19 pandemic, including its impacts across our businesses on demand, our operations and global supply chains, disruptions in the supply or changes in costs of raw materials, labor, product components or transportation services, including as a result of inflation, the results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay's business in general, see ViewRay's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and its Quarterly Reports on Form 10-Q, as updated periodically with the Company's other filings with the SEC. These forward-looking statements are made as of the date of this Current Report on Form 8-K, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

Exhibit Number Description <br> 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **VIEWRAY, INC.** | **VIEWRAY, INC.** |
| Date: March 14, 2023 | By: | /s/ Robert S. McCormack |
|  |  | Robert S. McCormack |
|  |  | Chief Legal Officer |

---